Cover Image
市場調查報告書

PharmaPoint:注意力不足過動症 (ADHD) - 全球醫藥品的預測與市場分析

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 404472
出版日期 內容資訊 英文 369 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:注意力不足過動症 (ADHD) - 全球醫藥品的預測與市場分析 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
出版日期: 2016年09月01日 內容資訊: 英文 369 Pages
簡介

本報告提供注意力不足過動症 (ADHD) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明、安全性、有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
  • 分類
  • 症狀
  • 預後

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
    • ADHD和確診的患者數
    • ADHD和確診的患者數:各年齡
    • ADHD和確診的患者數:性別
    • ADHD與確診的患者數:年齡調整
    • ADHD和確診的患者數:各子類型
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷、治療概要
  • 美國
  • EU5個國家
  • 日本

第6章 競爭評估

  • 概要
  • 產品簡介

第7章 未滿足需求與機會分析

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的有前途藥物概要等

第9章 現在、未來的企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Shire
    • Novartis
    • Janssen
    • Eli Lilly
    • Pfizer/Tris Pharma
    • Highland Therapeutics

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第11章 附錄

目錄
Product Code: GDHC125PIDR

Attention deficit hyperactivity disorder (ADHD) is a psychiatric disorder characterized by excessive levels of inattention, impulsivity, and hyperactivity, either alone or in combination, which has a significant social impact through disruptions at school, work, or home. The majority of children with the disorder will continue to experience symptoms into adolescence, resulting in significant functional impairment and poorer quality of life (QoL). While once thought to be limited to childhood, 30--50% of children diagnosed with ADHD continue to have problems into adulthood, resulting in 2--5% of adults having ADHD.

It is estimated that drug sales for ADHD in 2014 were approximately $6.1bn across the 7MM. Sales will steadily incline throughout the forecast period, despite the expiration of patents on a number of established brands, such as Shire's Adderall XR (extended release mixed amphetamine salts), Novartis' Ritalin LA (long-acting methylphenidate), Janssen Pharmaceuticals' Concerta (long-acting methylphenidate), and Eli Lilly's Strattera (atomoxetine). The high number of pipeline assets expected to launch prior to 2024, including both stimulant and non-stimulant therapies, will offset the sales decline from these mature brands.

Furthermore, the number of drug-treated patients will increase over the forecast period, driven by increased treatment rates throughout the 7MM, particularly in the adult age group. As a result, the global ADHD market value is expected to increase to $13.9bn in 2024, at a Compound Annual Growth Rate (CAGR) of 8.5%.

According to Rachel Markwick, Analyst: "Currently, the ADHD market is rife with unmet needs. These include a need for more treatment options, clinically relevant head-to-head comparisons between current marketed and pipeline drugs, improved diagnostic tests, and increased education and recognition of ADHD.

The main drivers of growth in the ADHD market over the forecast period are:

  • The launch of efficacious pipeline products with convenient oral formulations or less frequent dosing than currently available products.
  • An increase in treatment rates, which is expected across the 7MM and will bolster sales of current and emerging pipeline drugs.
  • The continued awareness and recognition of ADHD in the adult age group.

Historically, Shire, Novartis, Janssen Pharmaceuticals, and Eli Lilly have been the major players in the ADHD market because they have well-established brands. Shire's Adderall, Novartis' Ritalin, Janssen's Concerta, and Eli Lilly's Strattera have all become established brands in the initial treatment paradigm for ADHD. However, these brands will suffer from generic erosion early in the forecast period when their patents expire (except Adderall XR, which already faes competition). Therefore, these companies will all face major challenges in maintaining their positions in the ADHD marketplace, with the exception of Shire.

The report "PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024" provides an overview of ADHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report enables the following analysis:

  • Annualized ADHD market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ADHD therapeutics market.
  • Pipeline analysis: focus on 13 late-stage pipeline ADHD drugs discussing emerging trends as well as an overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global ADHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Alcobra, Amarantus, Curemark, Eli Lilly*, Highland Therapeutics*, Janssen*, Mallinckrodt, Medice, Neos Therapeutics, Neurovance, Nextwave Pharmaceuticals, Novartis*, Noven Pharmaceuticals, Pfizer+, Recordati, Rhodes Pharmaceuticals, Shionogi, Shire*, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Tris Pharma+, UCB.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
    • 3.2.1. Predominantly Inattentive Type
    • 3.2.2. Predominantly Hyperactive-Impulsive Type
    • 3.2.3. Combined Type
    • 3.2.4. Other Specified ADHD Type
    • 3.2.5. Unspecified Type
    • 3.2.6. Severity
  • 3.3. Symptoms
  • 3.4. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used Tables
    • 4.4.2. Forecast assumptions and methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for ADHD(2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of ADHD
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of ADHD
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of ADHD
    • 4.5.4. Age-Standardized Prevalence of ADHD
    • 4.5.5. Diagnosed Prevalent Cases of ADHD by Subtype
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Amphetamine(Stimulant)
    • 6.2.1. Dextroamphetamine
    • 6.2.2. Desoxyn(methamphetamine)
    • 6.2.3. Adderall XR(Mixed amphetamine Salts)
    • 6.2.4. Vyvanse(lisdexamphetamine dimesylate)
    • 6.2.5. Dyanavel XR(Liquid Amphetamine XR)
    • 6.2.6. Adzenys XR-ODT(Amphetamine Extended Release-Orally Disintegrating Tablet)
  • 6.3. Product Profiles - Methylphenidate(Stimulant)
    • 6.3.1. Ritalin LA
    • 6.3.2. Concerta
    • 6.3.3. Medikinet XL
    • 6.3.4. Metadate CD
    • 6.3.5. Methylin
    • 6.3.6. Focalin
    • 6.3.7. Daytrana
    • 6.3.8. Quillivant XR/Quillichew
    • 6.3.9. Aptensio XR
  • 6.4. Product Profiles - Non-stimulants
    • 6.4.1. Strattera(Atomoxetine Hydrochloride)
    • 6.4.2. Intuniv(Guanfacine Hydrochloride)
    • 6.4.3. Kapvay(Clonidine)
    • 6.4.4. Other Therapeutic Classes

7. Unmet Need and Opportunity Analysis

  • 7.1. Overview
  • 7.2. More Effective, Longer-Lasting, and/or Non-stimulant Treatment Options
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Clinically Relevant, Head-to-Head Comparisons
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Improved Diagnostic Tests
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Education and Recognition of ADHD
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Discontinuation and Long-Term Safety of Stimulants
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Class
  • 8.3. Overview of Promising Drugs in Clinical Development
  • 8.4. Promising Amphetamine Drugs in Clinical Development
    • 8.4.1. NT-0201(Liquid Amphetamine XR)
    • 8.4.2. SHP-465(Triple-Bead Mixed Amphetamine Salts)
    • 8.4.3. HLD-100(Dextroamphetamine MR)
    • 8.4.4. Amphetamine Transdermal System(Dextroamphetamine)
  • 8.5. Promising Methylphenidate Drugs in Clinical Development
    • 8.5.1. Cotempla XR-ODT(Extended-Release ODT Methylphenidate)
    • 8.5.2. Benjorna(Methylphenidate Hydrochloride MR)
  • 8.6. Promising Non-stimulant Drugs in Clinical Development
    • 8.6.1. SEP-225289(Dasotraline)
    • 8.6.2. Centanafadine SR
    • 8.6.3. SPN-810(Molindone Hydrochloride ER)
    • 8.6.4. SPN-812(Viloxazine Hydrochloride)
    • 8.6.5. Metadoxine ER
    • 8.6.6. Eltoprazine
    • 8.6.7. CM-4612
  • 8.7. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Shire
    • 9.3.2. Novartis
    • 9.3.3. Janssen
    • 9.3.4. Eli Lilly
    • 9.3.5. Pfizer/Tris Pharma
    • 9.3.6. Highland Therapeutics

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Driver and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed ADHD Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologists
    • 11.7.4. Managing Epidemiologists
    • 11.7.5. Global Director of Therapy Analysis and Epidemiology
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Classification of ADHD According to the DSM-V and ICD-10-CM
  • Table 2: Symptoms of ADHD
  • Table 3: Prognosis and Risks Associated with ADHD
  • Table 4: Risk Factors and Comorbidities for ADHD
  • Table 5: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD
  • Table 6: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages 3?17 Years
  • Table 7: 7MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of ADHD by Subtype, Ages ≥18 Years
  • Table 8: 7MM, Sources Not Used in Epidemiological Analysis of ADHD
  • Table 9: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages ≥3 Years, Select Years, 2014-2024
  • Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, N (Row%), 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages ≥3 Years, N (Row %), 2014
  • Table 12: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N (Row %), 2014
  • Table 13: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages ≥18 Years, Adults, N (Row %), 2014
  • Table 14: Rating Scales Used for ADHD
  • Table 15: Treatment Guidelines for Disease ADHD
  • Table 16: Most Prescribed Drugs for ADHD by Class in the Global Markets, 2014
  • Table 17: Country Profile - US
  • Table 18: Country Profile - 5EU
  • Table 19: Country Profile - Japan
  • Table 20: Leading Treatments for ADHD, 2015
  • Table 21: Product Profile - Dextroamphetamine
  • Table 22: Dextroamphetamine SWOT Analysis, 2015
  • Table 23: Global Sales Forecasts ($m) for Dextroamphetamine, 2014-2024
  • Table 24: Product Profile - Desoxyn
  • Table 25: Desoxyn SWOT Analysis, 2015
  • Table 26: Global Sales Forecasts ($m) for Desoxyn, 2014-2024
  • Table 27: Product Profile - Adderall XR
  • Table 28: Adderall XR SWOT Analysis, 2015
  • Table 29: Global Sales Forecasts ($m) for Adderall XR, 2014-2024
  • Table 30: Product Profile - Vyvanse
  • Table 31: Vyvanse SWOT Analysis, 2015
  • Table 32: Global Sales Forecasts ($m) for Vyvanse, 2014-2024
  • Table 33: Product Profile - Dyanavel XR
  • Table 34: Dyanavel SWOT Analysis, 2015
  • Table 35: Global Sales Forecasts ($m) for Dyanavel XR, 2014-2024
  • Table 36: Product Profile - Adzenys XR-ODT
  • Table 37: Adzenys XR-ODT SWOT Analysis, 2015
  • Table 38: Global Sales Forecasts ($m) for Adzenys XR-ODT, 2014-2024
  • Table 39: Product Profile - Ritalin LA
  • Table 40: Ritalin LA SWOT Analysis, 2015
  • Table 41: Global Sales Forecasts ($m) for Ritalin LA, 2014-2024
  • Table 42: Product Profile - Concerta
  • Table 43: Concerta SWOT Analysis, 2015
  • Table 44: Global Sales Forecasts ($m) for Concerta, 2014-2024
  • Table 45: Product Profile - Medikinet XL
  • Table 46: Medikinet SWOT Analysis, 2015
  • Table 47: Global Sales Forecasts ($m) for Medikinet XL, 2014-2024
  • Table 48: Product Profile - Metadate CD
  • Table 49: Incidence of TEAEs in a Pool of 3-4 Week Clinical Trials - Metadate CD
  • Table 50: Metadate CD SWOT Analysis, 2015
  • Table 51: Global Sales Forecasts ($m) for Metadate CD, 2014-2024
  • Table 52: Product Profile - Methylin
  • Table 53: Methylin SWOT Analysis, 2015
  • Table 54: Global Sales Forecasts ($m) for Methylin, 2014-2024
  • Table 55: Product Profile - Focalin
  • Table 56: TEAEs - Focalin
  • Table 57: TEAEs - Focalin XR
  • Table 58: Focalin SWOT Analysis, 2015
  • Table 59: Global Sales Forecasts ($m) for Focalin and Focalin XR, 2014-2024
  • Table 60: Product Profile - Daytrana
  • Table 61: Daytrana SWOT Analysis, 2015
  • Table 62: Global Sales Forecasts ($m) for Daytrana, 2014-2024
  • Table 63: Product Profile - Quillivant XR
  • Table 64: Quillichew Primary Efficacy Result
  • Table 65: Quillivant XR SWOT Analysis, 2015
  • Table 66: Global Sales Forecasts ($m) for Quillivant XR/Quillichew, 2014-2024
  • Table 67: Product Profile - Aptensio XR
  • Table 68: Summary of the Parallel Group Study - Aptensio XR
  • Table 69: Aptensio XR SWOT Analysis, 2015
  • Table 70: Global Sales Forecasts ($m) for Aptensio XR, 2014-2024
  • Table 71: Product Profile - Strattera
  • Table 72: Acute and Maintenance Efficacy Studies - Strattera
  • Table 73: Common TEAEs reported in acute trials in children and adolescents - Strattera
  • Table 74: Common TEAEs reported in acute trials in adults - Strattera
  • Table 75: Strattera SWOT Analysis, 2015
  • Table 76: Global Sales Forecasts ($m) for Strattera, 2014-2024
  • Table 77: Product Profile - Intuniv
  • Table 78: Fixed Dose Studies- Intuniv
  • Table 79: Intuniv SWOT Analysis, 2015
  • Table 80: Global Sales Forecasts ($m) for Intuniv, 2014-2024
  • Table 81: Product Profile - Kapvay
  • Table 82: Kapvay SWOT Analysis, 2015
  • Table 83: Global Sales Forecasts ($m) for Kapvay, 2014-2024
  • Table 84: Unmet Need and Opportunity in ADHD
  • Table 85: Drugs in Development, 2016
  • Table 86: Comparison of Therapeutic Classes in Development for ADHD, 2014-2024
  • Table 87: Product Profile - Liquid Amphetamine XR, NT-0201
  • Table 88: NT-0201 SWOT Analysis, 2015
  • Table 89: Global Sales Forecasts ($m) for NT-0201, 2014-2024
  • Table 90: Product Profile - Triple-Bead Mixed Amphetamine Salts (SHP-465)
  • Table 91: SHP-465 SWOT Analysis, 2015
  • Table 92: Global Sales Forecasts ($m) for SHP-465, 2014-2024
  • Table 93: Product Profile - HLD-100
  • Table 94: HLD-100 SWOT Analysis, 2015
  • Table 95: Global Sales Forecasts ($m) for HLD-100, 2014-2024
  • Table 96: Product Profile - Dextroamphetamine Transdermal Patch
  • Table 97: Dextroamphetamine Transdermal Patch SWOT Analysis, 2015
  • Table 98: Global Sales Forecasts ($m) for ATS, 2014-2024
  • Table 99: Product Profile - Cotempla XR-ODT
  • Table 100: Cotempla XR-ODT SWOT Analysis, 2015
  • Table 101: Global Sales Forecasts ($m) for Cotempla XR-ODT, 2014-2024
  • Table 102: Product Profile - Benjorna
  • Table 103: Benjorna SWOT Analysis, 2015
  • Table 104: Global Sales Forecasts ($m) for Benjorna, 2014-2024
  • Table 105: Product Profile - Dasotraline
  • Table 106: Dasotraline SWOT Analysis, 2015
  • Table 107: Global Sales Forecasts ($m) for dasotraline, 2014-2024
  • Table 108: Product Profile - Centanafadine SR
  • Table 109: Centanafadine SR SWOT Analysis, 2015
  • Table 110: Global Sales Forecasts ($m) for centanafadine SR, 2014-2024
  • Table 111: Product Profile - SPN-810
  • Table 112: SPN-810 SWOT Analysis, 2015
  • Table 113: Global Sales Forecasts ($m) for SPN-810, 2014-2024
  • Table 114: Product Profile - Viloxazine
  • Table 115: Viloxazine SWOT Analysis, 2015
  • Table 116: Global Sales Forecasts ($m) for Pipeline Viloxazine, 2014-2024
  • Table 117: Product Profile - Metadoxine ER
  • Table 118: Metadoxine ER SWOT Analysis, 2015
  • Table 119: Global Sales Forecasts ($m) for Metadoxine ER, 2014-2024
  • Table 120: Product Profile - Eltoprazine
  • Table 121: Eltoprazine SWOT Analysis, 2015
  • Table 122: Global Sales Forecasts ($m) for Eltoprazine, 2014-2024
  • Table 123: Product Profile - CM-4612
  • Table 124: CM-4612 SWOT Analysis, 2015
  • Table 125: Global Sales Forecasts ($m) for CM-4612, 2014-2024
  • Table 126: Drugs in Development, 2016
  • Table 127: Key Companies in the ADHD Market in the 7MM, 2014
  • Table 128: Shire's ADHD Portfolio Assessment, 2015
  • Table 129: Novartis' ADHD Portfolio Assessment, 2015
  • Table 130: Janssen's ADHD Portfolio Assessment, 2015
  • Table 131: Eli Lilly's ADHD Portfolio Assessment, 2015
  • Table 132: Pfizer/Tris Pharma's ADHD Portfolio Assessment, 2015
  • Table 133: Highland Therapeutics' ADHD Portfolio Assessment, 2016
  • Table 134: Global Sales Forecasts ($m) for ADHD, 2014-2024
  • Table 135: ADHD Market - Global Drivers and Barriers, 2014?2024
  • Table 136: Sales Forecasts ($m) for ADHD in the US, 2014-2024
  • Table 137: Key Events Impacting Sales for ADHD in the US, 2014-2024
  • Table 138: ADHD Market - Drivers and Barriers in the US, 2014?2024
  • Table 139: Sales Forecasts ($m) for ADHD in the 5EU, 2014-2024
  • Table 140: Key Events Impacting Sales for ADHD in the 5EU, 2014-2024
  • Table 141: ADHD Market - Drivers and Barriers in the 5EU, 2014?2024
  • Table 142: Sales Forecasts ($m) for ADHD in Japan, 2014-2024
  • Table 143: Key Events Impacting Sales for ADHD in Japan, 2014-2024
  • Table 144: ADHD Market - Drivers and Barriers in Japan, 2014?2024
  • Table 145: Key ADHD Launch Dates
  • Table 146: Key ADHD Patent Expiries
  • Table 147: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country, 2016

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of ADHD, Both Sexes, Ages ≥3 Years, Selected Years, 2014-2024
  • Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of ADHD, Both Sexes, 2014
  • Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of ADHD, Ages ≥3 Years, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of ADHD, Ages ≥3 Years, 2014
  • Figure 5: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages 3-17 Years, Children and Adolescents, N, 2014
  • Figure 6: 7MM, Diagnosed Prevalent Cases of ADHD, by Subtype, Ages ≥18 Years, Adults, N, 2014
  • Figure 7: Treatment Algorithm for ADHD in the 7MM
  • Figure 8: ADHD Therapeutics - Class of Therapy, 2016
  • Figure 9: ADHD - Phase II-III Pipeline, 2016
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in ADHD, 2014-2024
  • Figure 11: Clinical and Commercial Positioning of NT-0201
  • Figure 12: Clinical and Commercial Positioning of SHP-465
  • Figure 13: Clinical and Commercial Positioning of HLD-100
  • Figure 14: Clinical and Commercial Positioning of ATS
  • Figure 15: Clinical and Commercial Positioning of Cotempla XR-ODT
  • Figure 16: Clinical and Commercial Positioning of Benjorna
  • Figure 17: Clinical and Commercial Positioning of Dasotraline
  • Figure 18: Clinical and Commercial Positioning of Centanafadine SR
  • Figure 19: Clinical and Commercial Positioning of SPN-810
  • Figure 20: Clinical and Commercial Positioning of Viloxazine
  • Figure 21: Clinical and Commercial Positioning of Metadoxine ER
  • Figure 22: Clinical and Commercial Positioning of Eltoprazine
  • Figure 23: Clinical and Commercial Positioning of CM-4612
  • Figure 24: Global Sales of Branded Products for ADHD by Company, 2014-2024
  • Figure 25: Company Portfolio Gap Analysis in ADHD, 2014-2024
  • Figure 26: Shire SWOT Analysis in ADHD, 2014-2024
  • Figure 27: Novartis SWOT Analysis in ADHD, 2014-2024
  • Figure 28: Janssen SWOT in ADHD, 2014-2024
  • Figure 29: Eli Lilly SWOT Analysis in ADHD, 2014-2024
  • Figure 30: Pfizer/Tris Pharma SWOT Analysis in ADHD, 2014-2024
  • Figure 31: Highland Therapeutics SWOT Analysis in ADHD, 2014-2024
  • Figure 32: Global Sales for ADHD by Country, 2014 and 2024
  • Figure 33: Global Sales for ADHD by Drug Class, 2014 and 2024
  • Figure 34: Sales for ADHD by Drug Class in the US, 2014 and 2024
  • Figure 35: Sales for ADHD by Drug Class in the 5EU, 2014 and 2024
  • Figure 36: Sales for ADHD by Drug Class in Japan, 2014 and 2024
Back to Top